Multiple Myeloma is part of a spectrum of diseases labeled Plasma Cell Dyscrasia. Plasma cells are the cells responsible for forming antibodies against bacteria and foreign proteins. For reasons that are unclear, these cells lose their ability to respond to controlling signals from a hierarchy of immune cells. Plasma cells then divide and form abnormal proteins, which results in damage to the bone, the bone marrow, and/or other organs of the body.
The results of different therapeutic modalities for multiple Myeloma have not changed the course of the disease significantly since the late 1960's. Therefore, we believe that active research and new treatment modalities are a must to achieve our goals in controlling the disease.
The Cleveland Clinic Myeloma Research Program focuses on new drug development, as well as studying the tumor biology to modify its behavior. Over the past few years the research in the biology area has remarkably improved our understanding to develop less toxic and more rational maintenance therapy. This page will guide you through a list of the different clinical trials conducted at The Cleveland Clinic Myeloma Program.
In collaboration with the Cardiology heart failure unit, the Renal team, and the palliative care program research, and patient care is provided in a multidisciplinary fashion.
This page will provide you with the most recent updates relative to all the clinical trials conducted at the Cleveland Clinic Myeloma Program.